Please login to the form below

Not currently logged in
Email:
Password:

rheumatoid arthritis

This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).

Latest news

  • Gilead and Galapagos close in on filing for Xeljanz rival Gilead and Galapagos close in on filing for Xeljanz rival

    Belgian biotech gearing up for first approval. Galapagos and Gilead Sciences have a pair of positive phase 3 trials for their JAK inhibitor filgotinib in rheumatoid arthritis that they say make ... RA and the rest from other diseases such as psoriatic

  • AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

    Risankizumab is also being in clinical trials for a number of other inflammatory diseases, including Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. ... AbbVie has another inflammation treatment nearing the market,

  • EMA could follow FDA’s Xeljanz blood clot warning EMA could follow FDA’s Xeljanz blood clot warning

    Xeljanz is currently approved in both the US and EU for patients with rheumatoid arthritis (RA) and psoriatic arthritis, but at an authorised dose of 5mg, twice daily. ... In the EU and the US, this dose is higher than the authorised dose of 5 mg twice

  • Sanofi extends growth spurt thanks to Genzyme, Dupixent Sanofi extends growth spurt thanks to Genzyme, Dupixent

    Other new products in Sanofi’s portfolio are still not looking too buoyant, particularly Kevzara (sarilumab) for rheumatoid arthritis and high cholesterol therapy Praluent (alirocumab), both of which have struggled to

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    and the fatty liver disease non-alcoholic steatohepatitis (NASH) and selective JAK1 inhibitor f ilgotinib in rheumatoid arthritis. ... Also of great importance are two phase 3 studies, FINCH 1 and FINCH 3 of filgotinib in rheumatoid arthritis.

More from news
Approximately 55 fully matching, plus 398 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’ of improvement.

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    Pain has nervous and inflammatory components and we are interested in everything around the inflammatory process but also the central nervous system aspect of pain and adjunctive diseases such as rheumatoid ... arthritis and Parkinson’s.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics